Clark Estates Inc. NY Cuts Stock Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Clark Estates Inc. NY cut its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 17.3% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 39,100 shares of the medical equipment provider’s stock after selling 8,200 shares during the quarter. Lantheus comprises about 0.8% of Clark Estates Inc. NY’s portfolio, making the stock its 18th biggest position. Clark Estates Inc. NY owned approximately 0.06% of Lantheus worth $4,291,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Farallon Capital Management LLC raised its position in shares of Lantheus by 595.3% in the 1st quarter. Farallon Capital Management LLC now owns 1,483,227 shares of the medical equipment provider’s stock valued at $92,316,000 after purchasing an additional 1,269,900 shares during the last quarter. Swedbank AB acquired a new position in Lantheus in the 1st quarter worth approximately $26,346,000. Point72 Asset Management L.P. purchased a new stake in shares of Lantheus in the 2nd quarter valued at $26,794,000. Massachusetts Financial Services Co. MA acquired a new position in Lantheus during the third quarter valued at $25,955,000. Finally, LSV Asset Management raised its stake in shares of Lantheus by 27.9% during the 2nd quarter. LSV Asset Management now owns 640,950 shares of the medical equipment provider’s stock valued at $51,462,000 after buying an additional 139,647 shares during the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the stock. Redburn Atlantic initiated coverage on shares of Lantheus in a research report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price target on the stock. StockNews.com downgraded shares of Lantheus from a “buy” rating to a “hold” rating in a report on Thursday, November 21st. Truist Financial reiterated a “buy” rating and issued a $120.00 price objective (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. Finally, JMP Securities dropped their price target on Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a research report on Thursday, November 7th. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $122.50.

Lantheus Stock Down 1.6 %

NASDAQ:LNTH opened at $89.53 on Wednesday. The company has a market cap of $6.23 billion, a price-to-earnings ratio of 14.90 and a beta of 0.51. The company has a fifty day simple moving average of $102.80 and a two-hundred day simple moving average of $97.04. Lantheus Holdings, Inc. has a 52 week low of $50.20 and a 52 week high of $126.89.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.